Transthyretin Amyloidosis clinical trials at UCSF
1 in progress, 0 open to eligible people
Transthyretin Amyloidosis Outcome Survey (THAOS)
Sorry, in progress, not accepting new patients
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate. The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.
San Francisco, California and other locations